%%%%%%%%%%
`%%%%%%%%%%
`
`
`
`%%%%%%%%%%
`
`
`
`
`
`
`
` !"#$%
`%%%$!&'(()*+*,)-
`##!# #
`$
`.$/'012.$/
`34 5061768894
`''&'(()(>?)-
`!$#$
`$
`:'
`;<"#!'4=705'4
` $=8=120179'
`.$/'012.$/
`34 5061768894
`''&'(()A+?+)-
`$
`:'
`
`
`
`
`@!<"#!'4
` $=8=12017'
`BCDCEBFEGHIJKEKGKFLJKEMFLKBKGNJOPEGCEGKPEH
`QRSTRUVWXWYXQUSUZSU[\X]XY^XW\_X`a\_bRcdVZXeSb_SfXg_^_VbUVWTXgShXi_bbjkTXlUmYSUWYSd_TfX
`lWbhXUVbXgShXi_bbjkTXlUmYSUWYSd_TfXnVahXopgilqrfXsctYZ_VfXnVahXopsctYZ_VqrfXidYX
`udY[\USvUa_RWdaUcTXnVahXUVbXwx`X`ysXoaYcc_aWdt_cjfXpidYqrfX`RVXQ\USvUa_RWdaUcXnVbRTWSd_TXl72'
`UVbX`RVXQ\USvUa_RWdaUcXnVbRTWSd_TfXnVahXoaYcc_aWdt_cjfXp`RVqrfXUVbXzjbRTX{YScb|db_Xgx}}fX
`zjbRTXQ\USvUa_RWdaUcTXo~`srXnVahfXzjbRTXld^_Tad_Va_TXldvdW_bfXoaYcc_aWdt_cjfXpzjbRTqrfXUVbX
`xjcUVXQ\USvUa_RWdaUcTXnVahXopxQnqrXo_Ua\XdVbdtdbRUccjXUXpg_^_VbUVWXSYR[qXUVbXaYcc_aWdt_cjfX
`pg_^_VbUVWTqrX\_S_mjXTRmvdWXWYXQcUdVWd^^TXYtYXYSbdTXnVahXUVbXYtYXYSbdTXsy`XoaYcc_aWdt_cjfX
`pYtYqrXdWTXdVtUcdbdWjXaYVW_VWdYVTX^YSXW\_XUTT_SW_bXacUdvTXY^X~VdW_bX`WUW_TXQUW_VWXYThXff X
`
`Novo Nordisk Exhibit 2001
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00723
`Page 00001
`
`
`
`
`
! !"# $ !%&' ()*+,-! (. ./
`#0123401#356178"#91:30881;40<985121583"5=93>9?=915914@"538A71881:?38A@891:
`).%B(! (/.! '. C !. !. D !"# .'
`8@7#>1"#91:3015661891>"7718A"5:3568"A8@7#>1"5919"@8356?91714<A7":@>3565
`$ DE!.!... !. $ !!F . %G HI JKH
`#0123401#356178"#91:30881;40<985121583"5=93>9?=915914@"538A71881:?38A@891:
`).%B(! (/.! '. C !. !. D !"# .'
`8@7#>1"#91:3015661891>"7718A"5:3568"A8@7#>1"5919"@8356?91714<A7":@>3565
`$ DE!.!... !. $ !!F . %G HI JKH
L938385
`C!. $ .+'C ,-! )(! !( %G HI M H
`C!. $ .+'C ,-! )(! !( %G HI M H
`N O+' ' .C C /*!'. .!*(!'.! ! P !./..
`:30881;40<?A73>@0)/!. !.E(! !. Q '.!%G I H
36@71
`R+C /(NST%O* U '.... !.E(! $ !. !"# (! %G
` IV
`R+C /(NST%O* U '.... !.E(! $ !. !"# (! %G
` IV
`
`
`
WR%+B PC P !.( XYZNST%[(#35617\VA89"@83561:61
W]
`
`
`[!!.C ^YZNST%^_[ . !$ DE!*. $)'C!!$
`!(P.!... !. $ !!F . %G \IVHV\
``abcde
`f@403891:35 \\J?91A@403>3"5g
h1>"510
?ijklkmjnoplkmjqrl stlrjrmqum
`vuqowxylrwz{oy|qxwu}~jlplkmjl}j|ql mlullmqwoj|mqjojmnqu kwl
`
`
`Novo Nordisk Exhibit 2001
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00723
`Page 00002
`
`
`vuqowxylrwz{oy|qxwu}~jlplkmjl}j|ql mlullmqwoj|mqjojmnqu kwl
`
`
`Novo Nordisk Exhibit 2001
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00723
`Page 00002
`
`
`
`
`
!"#$%&'()*"+,-.+(.&.//(/0%1232-&/%)/&)4/0%
`1-&/%)/5)4%6789 :;<=:;>
`?<@AABCDE0&,#F.%&/-(/%)/+&G+)4+&H%/%,/0%.&-IJ*$%&'()&/J$%&'()
`7KL<=ABCDE+,#/0%-.(45'/(M/+,,5%E7L?N?L7E6<7<L6?77<NA
`@?<L6?@676L6@?<:DB;<ACE'%GG,(M/0%F&,/.(+)/%,/+)&GO5'(,&J*PQR
`SA7
`67@=<T6@<?=N6U7A6N@<=<A@U<7<UVBCDE:WEX ;U=<=BCDE
`:WEXW;>PQR
`?<7L6L7=A@7NU=N=BCDELL=7>?<KL<=7Y6
`67<7U=NV<@6BCDE=6YY7ZN6<7<?A<@6Y6<7@<=66L=
`=6=<>PQR
`[TY6?<KL<=A?@7=6=<7=<V<<\VUTA
`76@?@67L?N?VU=N?<7?<U=?<N6677<?TA6<<BCDE1,
`??YV>PQR
` WEW >?<<6=Y6@7BCDE<@7TAUL6Y=
`LA6U?]<?L6L67>^<7@?A<@T7A_`7@7@<>abb
`QR
` W>?<
`KL<=AA7<@T7AU7L<NA<@7<=T77L<7A
`<@6N6U>PQR
` W>SA@7?<=<N=L6?@66<7BCDEA?<N6
`677<?=6=<@6<??YV>PQR
` Wc>
`defghije
`k=l6?Am 99X<=L@7A=nYU6 99o<6<<D<_LL?<
`D@?<n>p^qq3rq 2!2s#$+O&.'0+*"t/+/G%4#u(GI%/0IG%)%vGI'(Gw+)xvwuE
`y(O-(5)4,t*+,-.+(.&.//(/0%1232&)4/0%1-&/%)/&/G%&,/5)4%.z9 :;<=:;>
`$+O&.'0+4+,'G(,%,#vwuE?UL@<=7?@L=7<LVAV<V?
`U?@6=6YYA6N67@<<?V?YLL=TA<K<==ANEN
`<=7T6?6<?TA<?UL6=AN@<D{BV=LL+4%J*PQR
`_76?>
`
`
`Novo Nordisk Exhibit 2001
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00723
`Page 00003
`
`
`1-&/%)/5)4%6789 :;<=:;>
`?<@AABCDE0&,#F.%&/-(/%)/+&G+)4+&H%/%,/0%.&-IJ*$%&'()&/J$%&'()
`7KL<=ABCDE+,#/0%-.(45'/(M/+,,5%E7L?N?L7E6<7<L6?77<NA
`@?<L6?@676L6@?<:DB;<ACE'%GG,(M/0%F&,/.(+)/%,/+)&GO5'(,&J*PQR
`SA7
`67@=<T6@<?=N6U7A6N@<=<A@U<7<UVBCDE:WEX ;U=<=BCDE
`:WEXW;>PQR
`?<7L6L7=A@7NU=N=BCDELL=7>?<KL<=7Y6
`67<7U=NV<@6BCDE=6YY7ZN6<7<?A<@6Y6<7@<=66L=
`=6=<>PQR
`[TY6?<KL<=A?@7=6=<7=<V<<\VUTA
`76@?@67L?N?VU=N?<7?<U=?<N6677<?TA6<<BCDE1,
`??YV>PQR
` WEW >?<<6=Y6@7BCDE<@7TAUL6Y=
`LA6U?]<?L6L67>^<7@?A<@T7A_`7@7@<>abb
`QR
` W>?<
`KL<=AA7<@T7AU7L<NA<@7<=T77L<7A
`<@6N6U>PQR
` W>SA@7?<=<N=L6?@66<7BCDEA?<N6
`677<?=6=<@6<??YV>PQR
` Wc>
`defghije
`k=l6?Am 99X<=L@7A=nYU6 99o<6<<D<_LL?<
`D@?<n>p^qq3rq 2!2s#$+O&.'0+*"t/+/G%4#u(GI%/0IG%)%vGI'(Gw+)xvwuE
`y(O-(5)4,t*+,-.+(.&.//(/0%1232&)4/0%1-&/%)/&/G%&,/5)4%.z9 :;<=:;>
`$+O&.'0+4+,'G(,%,#vwuE?UL@<=7?@L=7<LVAV<V?
`U?@6=6YYA6N67@<<?V?YLL=TA<K<==ANEN
`<=7T6?6<?TA<?UL6=AN@<D{BV=LL+4%J*PQR
`_76?>
`
`
`Novo Nordisk Exhibit 2001
`Mylan Pharms. Inc.v. Novo Nordisk A/S
`IPR2023-00723
`Page 00003
`
`
`
`
`
!"#
$%&'()*+%,$% ')-.'&
`'*&$*/$%--)01%- %/ 23 4
`
`5*+&'&%&, $-' ,*678
`'*&$*/$%--)01%- %/ 23 4
`
`5*+&'&%&, $-' ,*678